| abstract |
A set of pharmaceutical dosage forms is provided, each comprising at least two therapeutic agents selected from (a) and estrogen (b) and androgen, and (c) an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of female sexual dysfunction (FSD) or postmenopausal sexual avoidance (PMSA), said dosage forms being adapted for intravaginal administration. A method of treatment of FSD or PMSA comprises administering intravaginally in a treatment regimen extending over a period of at least 2 days, dosage forms at least a portion of which comprise two or more therapeutic agents selected from (a) an estrogen. (b) an androgen, and (c) an antimuscarinic, in total and relative dosage amounts that are therapeutically effective in treatment of FSD or PMSA, wherein no more than one dosage form is administered on any day. Also provided is a kh useful in implementing such a treatment regimen. |